Biodesix (BDSX)
Nasdaq Market Closed
Biodesix, Inc. is a diagnostics company focused on lung disease, with a commercial strategy built around blood-based testing and related laboratory services. The company’s core market is lung cancer, where clinicians often need additional information to support diagnosis, treatment planning, and patient management. Its tests are designed to complement imaging, tissue biopsy, and other clinical inputs, helping physicians make more informed decisions in a disease area where timing and accuracy can be critical.
The company operates as a single business segment and earns revenue from two main activities. The first is clinical diagnostic testing, including blood-based lung tests and tests developed for COVID-related use. The second is work performed for biopharmaceutical customers, such as diagnostic research, clinical trial testing, assay development, and support for companion diagnostic programs. These services are typically governed by individual contracts and may be used by drug developers as they evaluate targeted therapies or identify patient groups for clinical studies.
Biodesix sits at the intersection of molecular diagnostics, proteomics, genomics, and precision medicine. Its business depends on test adoption by healthcare providers, reimbursement from payers, and demand from pharmaceutical and biotechnology companies. As a listed diagnostics stock, BDSX gives investors exposure to a specialised healthcare company whose growth is tied to the expanding role of data-driven testing in lung disease care and drug development.
Last updated
- Market Cap
- 166.73M
- P/E
- —
- P/FCF
- —
- P/S
- 1.74
- Enterprise Value
- 187.65M
- Sector
- Health Care
- Industry
- Medical Laboratories
- Address
- 919 WEST DILLON ROAD, LOUISVILLE, CO, 80027
Biodesix to Participate in Upcoming Investor Conferences
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
Biodesix to Participate in Upcoming Investor Conferences
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS
Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
Biodesix to Present at TD Cowen 45th Annual Health Care Conference
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study
Biodesix Announces Third Quarter 2024 Results and Highlights
Laboratory-Developed Tests (LDTs) World Market Forecast Report to 2028, with Coverage of the Effects of the FDA's New "Medical Devices: Laboratory Developed Tests" Rule, Passed in April 2024
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 166.73M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 187.65M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 18.26
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.74
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -9.74
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.95
- EPS
- -3.09
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -25.1M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -349.95%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -33.77%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 5.09
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.82
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.82
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.76
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 72.67K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 16.1
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 25.56M | 28.76M | 21.77M | 20.02M | 17.96M |
| Gross profit | 21.35M | 23.88M | 17.66M | 15.99M | 14.26M |
| Operating income | -6.2M | -1.97M | -7.05M | -9.72M | -9.14M |
| EBITDA | -4.8M | -579K | -5.64M | -8.26M | -7.62M |
| Net income | -7.79M | -3.98M | -8.72M | -11.47M | -11.1M |
| Basic EPS | -0.81 | -0.43 | -1.16 | -1.6 | -1.52 |
| Diluted EPS | -0.81 | -0.43 | -1.16 | -1.6 | -1.52 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 94.64M | 87.48M | 88.72M | 87.74M | 86.24M |
| Total liabilities | 85.51M | 89.94M | 90.44M | 86.6M | 75.18M |
| Total equity | 9.13M | -2.47M | -1.72M | 1.14M | 11.06M |
| Cash & equivalents | 25.57M | 18.99M | 16.6M | 20.73M | 17.6M |
| Current assets | 40.91M | 32.52M | 33.4M | 32.45M | 29.62M |
| Current liabilities | 14.49M | 17.44M | 18.15M | 15.16M | 13.32M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -10.17M | 778K | -8.88M | -6.57M | -8.6M |
| Investing cash flow | -144K | -104K | -67K | -95K | -137K |
| Financing cash flow | 16.9M | 1.71M | 4.82M | 9.79M | 97K |
| Change in cash | 6.59M | 2.38M | -4.12M | 3.13M | -8.64M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 424B3 — BIODESIX INC | View Filing | |
| edgar index | EFFECT — BIODESIX INC | View Filing | |
| edgar index | S-3 — BIODESIX INC | View Filing | |
| edgar index | 8-K — BIODESIX INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — BIODESIX INC | View Filing | |
| edgar index | SCHEDULE 13G/A — BIODESIX INC | View Filing | |
| edgar index | 8-K — BIODESIX INC | View Filing | |
| edgar index | 10-Q — BIODESIX INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — BIODESIX INC | View Filing | |
| edgar index | DEF 14A — BIODESIX INC | View Filing | |
| edgar index | DEFA14A — BIODESIX INC | View Filing | |
| edgar index | ARS — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| form 4 | Form 4 — PATIENCE JOHN | View Filing | |
| form 4 | Form 4 — PATIENCE JOHN | View Filing | |
| form 4 | Form 4 — PATIENCE JOHN | View Filing | |
| form 4 | Form 4 — PATIENCE JOHN | View Filing | |
| form 4 | Form 4 — PATIENCE JOHN | View Filing | |
| edgar index | 8-K — BIODESIX INC | View Filing | |
| edgar index | 10-K — BIODESIX INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 144 — BIODESIX INC | View Filing | |
| form 4 | Form 4 — O'Kane Kieran | View Filing | |
| form 4 | Form 4 — Pestano Gary Anthony | View Filing | |
| form 4 | Form 4 — Hutton Scott | View Filing | |
| form 4 | Form 4 — Cowie Robin Harper | View Filing | |
| form 4 | Form 4 — Vazquez Chris | View Filing | |
| form 4 | Form 4 — O'Kane Kieran | View Filing | |
| form 4 | Form 4 — O'Kane Kieran | View Filing | |
| form 4 | Form 4 — Pestano Gary Anthony | View Filing | |
| form 4 | Form 4 — Pestano Gary Anthony | View Filing | |
| form 4 | Form 4 — Hutton Scott | View Filing | |
| form 4 | Form 4 — Hutton Scott | View Filing | |
| form 4 | Form 4 — Cowie Robin Harper | View Filing | |
| form 4 | Form 4 — Cowie Robin Harper | View Filing | |
| form 4 | Form 4 — Vazquez Chris | View Filing | |
| form 4 | Form 4 — Vazquez Chris | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| form 4 | Form 4 — Hutton Scott | View Filing | |
| form 4 | Form 4 — Pestano Gary Anthony | View Filing | |
| form 4 | Form 4 — O'Kane Kieran | View Filing | |
| form 4 | Form 4 — Vazquez Chris | View Filing | |
| form 4 | Form 4 — Cowie Robin Harper | View Filing | |
| form 4 | Form 4 — Hutton Scott | View Filing | |
| form 4 | Form 4 — Hutton Scott | View Filing | |
| form 4 | Form 4 — Hutton Scott | View Filing | |
| form 4 | Form 4 — Pestano Gary Anthony | View Filing | |
| form 4 | Form 4 — Pestano Gary Anthony | View Filing | |
| form 4 | Form 4 — Pestano Gary Anthony | View Filing | |
| form 4 | Form 4 — O'Kane Kieran | View Filing | |
| form 4 | Form 4 — O'Kane Kieran | View Filing | |
| form 4 | Form 4 — O'Kane Kieran | View Filing | |
| form 4 | Form 4 — Vazquez Chris | View Filing | |
| form 4 | Form 4 — Vazquez Chris | View Filing | |
| form 4 | Form 4 — Vazquez Chris | View Filing | |
| form 4 | Form 4 — Cowie Robin Harper | View Filing | |
| form 4 | Form 4 — Cowie Robin Harper | View Filing | |
| form 4 | Form 4 — Cowie Robin Harper | View Filing | |
| edgar index | S-8 — BIODESIX INC | View Filing | |
| edgar index | 4 — BIODESIX INC | View Filing | |
| edgar index | SCHEDULE 13D/A — BIODESIX INC | View Filing |